Granules Life Sciences gets U.S. FDA’s inspection report

Generic drugmaker Granules India’s Hyderabad-based pharmaceutical formulation intermediates and finished dosages manufacturing subsidiary Granules Life Sciences (GLS) has received establishment inspection report from the U.S. Food and Drug Administration (FDA).

The development confirms the facility’s compliance with FDA quality standards and regulatory requirements, the parent company said on Friday, announcing the EIR. The facility underwent its first U.S. FDA inspection from July 28 to August 01 which concluded with one observation.